Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EAT-DARE-AF: Dapagliflozin for AF Recurrence After Catheter Ablation
NCT07331727Not yet recruiting
- Sponsor
- Shanghai Chest Hospital
- Start
- Jan 2026
- Primary completion
- Sep 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of dapagliflozin in Atrial fibrillation (AFib) (2 arms), sponsored by Shanghai Chest Hospital. Primary endpoint: Atrial fibrillation burden at 3 months. Planned start Jan 2026; status: not yet recruiting.
02
Drugs
dapagliflozin
03
Conditions
Atrial fibrillation (AFib)
Beyond the preview
Go deeper on NCT07331727.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07331727.